Ken Griffin Relay Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 36,100 shares of RLAY stock, worth $120,935. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,100

Previous 21,800 65.6%

Holding current value

$120,935

Previous $57,000 117.54%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$2.62 - $4.92 $915,978 - $1.72 Million	-349,610 Reduced 50.9%	337,268 $883,000
Q4 2024 Feb 14, 2025	SELL	$4.12 - $6.8 $9.16 Million - $15.1 Million	-2,222,493 Reduced 76.39%	686,878 $2.83 Million
Q3 2024 Nov 14, 2024	BUY	$6.23 - $9.51 $10.9 Million - $16.6 Million	1,746,035 Added 150.09%	2,909,371 $20.6 Million
Q2 2024 Aug 14, 2024	BUY	$5.9 - $8.02 $5.46 Million - $7.43 Million	926,136 Added 390.45%	1,163,336 $7.58 Million
Q1 2024 May 15, 2024	SELL	$7.5 - $12.07 $2.7 Million - $4.35 Million	-360,394 Reduced 60.31%	237,200 $1.97 Million
Q4 2023 Feb 14, 2024	SELL	$6.01 - $11.48 $6.52 Million - $12.5 Million	-1,085,255 Reduced 64.49%	597,594 $6.58 Million
Q3 2023 Nov 14, 2023	BUY	$8.24 - $12.97 $11.3 Million - $17.8 Million	1,374,834 Added 446.35%	1,682,849 $14.2 Million
Q2 2023 Aug 14, 2023	BUY	$9.99 - $18.27 $2.87 Million - $5.25 Million	287,296 Added 1386.63%	308,015 $3.87 Million
Q1 2023 May 15, 2023	SELL	$15.0 - $22.76 $1.7 Million - $2.59 Million	-113,641 Reduced 84.58%	20,719 $341,000
Q4 2022 Feb 14, 2023	SELL	$14.16 - $24.02 $1.68 Million - $2.84 Million	-118,380 Reduced 46.84%	134,360 $2.01 Million
Q3 2022 Nov 14, 2022	BUY	$18.07 - $31.37 $4.04 Million - $7.02 Million	223,821 Added 773.96%	252,740 $5.65 Million
Q2 2022 Aug 15, 2022	SELL	$13.31 - $34.88 $947,339 - $2.48 Million	-71,175 Reduced 71.11%	28,919 $484,000
Q1 2022 May 16, 2022	SELL	$20.26 - $32.36 $3.09 Million - $4.94 Million	-152,665 Reduced 60.4%	100,094 $3 Million
Q4 2021 Feb 14, 2022	BUY	$26.0 - $37.03 $1.73 Million - $2.46 Million	66,512 Added 35.71%	252,759 $7.76 Million
Q3 2021 Nov 15, 2021	BUY	$29.75 - $37.99 $1.76 Million - $2.24 Million	58,996 Added 46.36%	186,247 $5.87 Million
Q2 2021 Aug 16, 2021	BUY	$27.5 - $38.19 $13,145 - $18,254	478 Added 0.38%	127,251 $4.66 Million
Q1 2021 May 17, 2021	BUY	$32.52 - $61.53 $2.07 Million - $3.92 Million	63,776 Added 101.24%	126,773 $4.38 Million
Q4 2020 Feb 16, 2021	BUY	$35.51 - $54.03 $316,181 - $481,083	8,904 Added 16.46%	62,997 $2.62 Million
Q3 2020 Nov 16, 2020	BUY	$32.81 - $45.1 $1.77 Million - $2.44 Million	54,093 New	54,093 $2.3 Million

Others Institutions Holding RLAY

# of Institutions

213

Shares Held

172M

Call Options Held

Put Options Held

36.1K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $403M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account